This is a working overview of carcinogenicity, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-23 and is reviewed periodically as new material appears.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
A notable application of these crystals is the development of quantum dots. Peidong Yang, another researcher from the University of California, Berkeley, is also notable for his contributions to the development of 1-dimensional nanostructures. The Yang group has active research projects in the areas of nanowire photonics, nanowire-based solar cells, nanowires for solar to fuel conversion, nanowire thermoelectrics, nanowire-cell interface, nanocrystal catalysis, nanotube nanofluidics, and plasmonics.
=== Anxiety disorders === KOR antagonists have demonstrated anxiolytic efficacy in preclinical stress models and early clinical evaluation. Early generation antagonists such as JDTic and nor-BNI produced anxiolytic-like effects in GAD, PTSD, and panic disorder models. However their long duration of action and off-target toxicities limited clinical development. Contemporary short-acting antagonists such as aticaprant are being evaluated for anxiety indications given their improved pharmacokinetic profiles and reduced toxicity burden.
Lexanopadol (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known by its developmental code name GRT-6006, is an opioid receptor modulator which was under development for the treatment of pain. It is taken orally. The drug acts as a dual agonist of the μ-opioid receptor and nociceptin receptor. It is thought that the combination of these activities may confer enhanced analgesic efficacy. Lexanopadol was under development by Grünenthal. It reached phase 1 or 2 clinical trials prior to the discontinuation of its development, with no further development reported by 2016. The drug was a follow-on compound to cebranopadol (GRT-6005).
Sources: en.wikipedia.org
For promotion from the Secondary level (Class IX-X) to the Senior Secondary level (Class XI-XII), a student must obtain, for all subjects (or best five if six subjects are taken), 33% overall, without any minimum theory mark requirement. Initially, the passing criteria were set such that a student had to get 33% in both the theory and practical components. However, an exemption was initially granted to students who wrote the exam in 2018, as they had gone through the old CCE system the previous year. However, CBSE later extended this relief for students writing the exam from 2019 and later as well. Students who do not manage to pass up to two subjects can write the compartment in those subjects in July. Those who fail a compartment or three or more subjects must retake all subjects taken the following year.
Alkali metal cations do not usually form coordination complexes with simple Lewis bases due to their low charge of just +1 and their relatively large size; thus the Li+ ion forms most complexes and the heavier alkali metal ions form less and less (though exceptions occur for weak complexes). Lithium in particular has a very rich coordination chemistry in which it exhibits coordination numbers from 1 to 12, although octahedral hexacoordination is its preferred mode. In aqueous solution, the alkali metal ions exist as octahedral hexahydrate complexes [M(H2O)6]+, with the exception of the lithium ion, which due to its small size forms tetrahedral tetrahydrate complexes [Li(H2O)4]+; the alkali metals form these complexes because their ions are attracted by electrostatic forces of attraction to the polar water molecules. Because of this, anhydrous salts containing alkali metal cations are often used as desiccants. Alkali metals also readily form complexes with crown ethers (e.g. 12-crown-4 for Li+, 15-crown-5 for Na+, 18-crown-6 for K+, and 21-crown-7 for Rb+) and cryptands due to electrostatic attraction.
== Further reading == Manila, S.; Recan, D.; Sewry, C. A.; Hoeltzenbein, M.; Llense, S.; Leturcq, F.; Deburgrave, N.; Barbot, J.-C.; Man, Nguyen thi (1998-05-01). "Mutations in Emery–Dreifuss Muscular Dystrophy and their Effects on Emerin Protein Expression". Human Molecular Genetics. 7 (5): 855–864. doi:10.1093/hmg/7.5.855. ISSN 0964-6906. PMID 9536090. Ziat, Esma; Bertrand, Anne T. (2015-01-01). "FHL1 protein isoforms in Emery–Dreifuss muscular dystrophy". Orphanet Journal of Rare Diseases. 10 (2): O18. doi:10.1186/1750-1172-10-S2-O18. ISSN 1750-1172. PMC 4652543.
== Structure == Fibrous bands anchoring the skin to the deep fascia Collagen and elastin fibers attaching it to the dermis Fat is absent from the eyelids, clitoris, penis, much of pinna, and scrotum Blood vessels on route to the dermis Lymphatic vessels on route from the dermis The glandular part of some sweat glands; mammary glands lie entirely within the subcutaneous tissue (which are modified apocrine sweat glands) Cutaneous nerves and free endings Hair follicle roots Ruffini and Pacinian corpuscles Mast cells Bursae, in the space overlying joints in order to facilitate smooth passage of overlying skin Fine, flat sheets of muscle, in certain locations, including the scalp, face, hand, nipple, and scrotum, called the panniculus carnosus The hypodermis forms an important insulating layer and/or food store in some animals, such as whales and hibernating mammals. In some plants, the hypodermis is a layer of cells immediately below the epidermis of leaves. It is often mechanically strengthened, for example, in pine leaves, forming an extra protective layer or a water storage tissue.
Sources: en.wikipedia.org
Navid Kermani (German: [naˈviːd kɛʁˈmaːni]; Persian: نوید کرمانی; [næˈviːd keɾmɒːˈniː]; born 27 November 1967 in Siegen) is a German writer and orientalist. He is the author of several novels as well as books and essays on Islam, the Middle East and Christian-Muslim dialogue. He has won numerous prizes for his literary and academic work, including the Peace Prize of the German Publishers' Association on 18 June 2015.
=== Regulatory flexibility === Emergency regulatory pathways created during the pandemic demonstrated the potential for more flexible oversight frameworks. The FDA's Emergency Use Authorizations for COVID-19 tests expanded point-of-care and over-the-counter testing options, establishing precedents that may influence future regulatory approaches for other diagnostic tests.
== Overdose == CPA is relatively safe in acute overdose. It is used at very high doses of up to 300 mg/day by mouth and 700 mg per week by intramuscular injection. For comparison, the dose of CPA used in birth control pills is 2 mg/day. There have been no deaths associated with CPA overdose. There are no specific antidotes for CPA overdose, and treatment should be symptom-based. Gastric lavage can be used in the event of oral overdose within the last 2 to 3 hours.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.